Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
NATCO Pharma is a Hyderabad-based pharmaceutical company specialising in complex, limited-competition generics and first-to-file Para IV opportunities in the US (notably generic Revlimid/lenalidomide, a major profit driver in recent years), alongside a domestic branded oncology and hepatitis franchise. It also has a fast-growing crop health sciences (agrochemicals) division and manufactures APIs for captive and merchant sale. Earnings are lumpy by design, tied to exclusivity windows and settlement-driven US launches rather than steady base business.
It is one of India's leading niche/complex generics players in oncology and Para IV litigation-driven launches.
NATCO Pharma Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from NATCO Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 79.20 | 105.26 | 77.34 |
| Book value / share (₹) | 515.15 | 425.27 | 326.99 |
| Return on equity | 15.4% | 24.8% | 23.7% |
| Return on capital employed | 13.1% | 25.5% | 26.4% |
| Operating margin | 30.2% | 44.3% | 39.1% |
| Net margin | 34.8% | 42.5% | 34.7% |
| EBITDA | ₹1,437 Cr | ₹2,196 Cr | ₹1,751 Cr |
| Free cash flow | ₹1,377 Cr | ₹1,185 Cr | ₹853 Cr |
| Total debt | ₹706 Cr | ₹273 Cr | ₹363 Cr |
| Debt to equity | 0.08 | 0.04 | 0.06 |
| Interest coverage | 33.5 | 82.0 | 81.5 |
| Current ratio | 3.01 | 5.59 | 4.14 |
| Shares outstanding | 17,90,00,000 | 17,90,00,000 | 17,90,00,000 |
Open the full income statement, balance sheet and cash flow for NATCOPHARM →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.